Skip to main content Skip to navigation
Purified NA/LE Mouse Anti-Human CD119
Product Details
Down Arrow Up Arrow


BD Pharmingen™
IFN- gamma receptor alpha chain
Human (QC Testing)
Mouse IgG1, κ
Human IFN-γRα
ELISA (Routinely Tested), Flow cytometry, Neutralization (Tested During Development)
1.0 mg/ml
VI C-110
3459
AB_396745
No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
RUO


Preparation And Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. An isotype control should be used at the same concentration as the antibody of interest.
  3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
557531 Rev. 3
Antibody Details
Down Arrow Up Arrow
GIR-208

The GIR-208 antibody recognizes the extracellular region of CD119 which is also known as the alpha chain subunit (80-95 kDa glycoprotein) of the human interferon-γ receptor (IFN-γRα).  The functionally active-form of the human IFN-γ receptor consists of two (or more) subunits, with IFN-γRα responsible for IFN-γ binding and both the IFN-γRα and β chains required for the transduction of biologic responses.  The IFN-γ receptor α chain (CD119) is expressed on the surface of most human cells (except mature erythrocytes) including monocytes, macrophages, T cells, B cells, NK cells, neutrophils, fibroblasts, epithelial cells, and endothelium.  Binding of 125I-labeled GIR-208 antibody to IFN-γRα+ cells is reported to be specifically inhibited in the presence of excess IFN-γ.  GIR-208 does not cross react with IFN-γ as tested by ELISA. The ability of this antibody to bind to IFN-γ receptors of species other than human has not been determined. The immunogen used to generate this hybridoma was human IFN-γRα purified from human placenta.  The GIR- 208 has been reported to block the binding of 125I-human IFN-γ to IFN-γRα+ cells as well as purified, soluble human IFN-γRα. GIR-208 is a neutralizing antibody that has been shown to neutralize the anti-viral activity of IFN-γ on WISH cells in a dose-dependent fashion.

557531 Rev. 3
Format Details
Down Arrow Up Arrow
NA/LE
NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.
NA/LE
557531 Rev.3
Citations & References
Down Arrow Up Arrow

Development References (3)

  1. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997; 15:563-591. (Biology). View Reference
  2. Peyman JA, Hammond GL. Localization of IFN-gamma receptor in first trimester placenta to trophoblasts but lack of stimulation of HLA-DRA, -DRB, or invariant chain mRNA expression by IFN-gamma. J Immunol. 1992; 149(8):2675-2680. (Biology: Flow cytometry). View Reference
  3. Sheehan KC, Calderon J, Schreiber RD. Generation and characterization of monoclonal antibodies specific for the human IFN-gamma receptor. J Immunol. 1988; 140(12):4231-4237. (Biology: Blocking, Neutralization, Western blot). View Reference
557531 Rev. 3

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.